<DOC>
	<DOC>NCT01987102</DOC>
	<brief_summary>An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the [6R] 5,10-methylenetetrahydrofolate Dose with Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity during Treatment of Osteosarcoma Patients</brief_summary>
	<brief_title>Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients must have histological evidence of osteosarcoma including metastatic osteosarcoma.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>rescue treatment</keyword>
</DOC>